Patent details
EP4415693 Title: FORMULATIONS OF FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF
Basic Information
- Publication number:
- EP4415693
- PCT Application Number:
- US2022078097
- Type:
- European Patent Granted for LU
- Legal Status:
- Unitary Effect Registered
- Application number:
- EP228130084
- PCT Publication Number:
- WO2023064886
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- FORMULATIONS OF FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF
- French Title of Invention:
- FORMULATIONS DE PROTÉINES CHIMÉRIQUES DU FACTEUR VIII ET LEURS UTILISATIONS
- German Title of Invention:
- FORMULIERUNGEN VON CHIMÄREN FAKTOR-VIII-PROTEINEN UND VERWENDUNGEN DAVON
- SPC Number:
Unitary Effect
- Unitary Effect Requested:
- Yes
- Unitary Effect Request Filing Date:
- 06/03/2026
- Link to UPP Register:
- European Patent Register
- Unitary Effect Request Withdrawal Date:
- Unitary Effect Status:
- Unitary Effect Registered
- Unitary Effect Acceptance Decision Date:
- 11/03/2026
- Unitary Effect Rejection Decision Date:
- Unitary Effect Date:
- 18/02/2026
- Unitary Effect Registration Date:
- 11/03/2026
- Unitary Effect Re-establishment of rights Filing Date:
- Unitary Effect Re-establishment of rights EPO Decision :
- Unitary Effect Re-establishment of rights EPO Decision Date:
- Explanatory Text UE:
- Safety Net Request Date:
- Safety Net Decision Date:
- Safety Net Decision Outcome:
- SPC Number:
Dates
- Filing date:
- 14/10/2022
- Grant date:
- 18/02/2026
- EP Publication Date:
- 21/08/2024
- PCT Publication Date:
- 20/04/2023
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 18/02/2026
- EP B1 Publication Date:
- 18/02/2026
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- Expiration date:
- 14/10/2042
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 11/02/2026
- Name:
- Bioverativ Therapeutics Inc.
- Address:
- 225 Second Avenue, Waltham MA 02451, United States (US)
Inventor
1
- Name:
- MAULDIN, Randall
- Address:
- United States (US)
2
- Name:
- MCCOY, Timothy R.
- Address:
- United States (US)
3
- Name:
- CARLAGE, Tyler
- Address:
- United States (US)
4
- Name:
- TAZI, Loubna Mzaalak
- Address:
- United States (US)
Priority
- Priority Number:
- 202163256432 P
- Priority Date:
- 15/10/2021
- Priority Country:
- United States (US)
Classification
- IPC classification:
- A61K 9/19; A61K 47/02; A61K 47/18; A61K 47/26; A61P 7/04; A61K 47/10;
Publication
European Patent Bulletin
1
- Issue number:
- 202608
- Publication date:
- 18/02/2026
- Description:
- Grant (B1)
2
- Issue number:
- 202616
- Publication date:
- 15/04/2026
- Description:
- Unitary Effect Request Receipt
3
- Issue number:
- 202616
- Publication date:
- 15/04/2026
- Description:
- Unitary Effect Request Acceptance
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|